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Abstract
The molecular cloning and biological analyses of cytokines have led us to a general understanding of their pleiotropism and redundancy.
These features have been ascribed to the composition of cytokine receptor complexes, which include a signal-transducing receptor subunit
that is used by all members of a cytokine family and a binding subunit that is specific for each cytokine. Even though a given cytokine uses
the same receptor complex when binding to various cell types, the cytokine elicits quite specific and distinct biological responses in different
types of cells. Even in the same type of cell, the responses to a given cytokine could vary depending on the location of the cell and the
condition of its microenvironment. Important mediators for the main cytokine signal-transduction pathway are the Janus kinases (Jaks) and
signal transducer and activator of transcription (STATs). Selective usage of members of the Jak and STAT families by a given cytokine
receptor is partly responsible for the specificity of cytokine action. In addition to the Jak–STAT pathway, a cytokine receptor complex can
simultaneously operate multiple signal-transduction pathways, which usually express contradictory properties. These contradictory signals
from a single cytokine are orchestrated to evoke a unified biological response in the cell. Here we discuss the molecular mechanisms that
regulate how the cell specificity of cytokine signals is regulated, especially focusing on the IL-6/gp130 system.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cytokines play pivotal roles in the regulation of various
biological responses, such as immune responses, inflamma-
tion, hematopoiesis, oncogenesis, neurogenesis, and even in
the early development of embryos, including the establish-
ment of the body axis and cell polarity. Cytokines transduce
signals from the outside to the inside of cells through
specific receptors. The combination of cytokines and their
effective concentrations at specific sites can differ, and the
action of a given cytokine on a given tissue or cell type can
be affected by the microenvironment of the target cell.
Microenvironments can reflect different physiological con-
ditions, e.g., a steady, stressed, inflamed, or tumor-bearing
state. For example, a typical pleiotropic cytokine, IL-6,
induces B cell differentiation into antibody-producing
plasma cells, T-cell growth and differentiation, differentia-
tion of the myeloid leukemic cell line M1 into macrophages,
and the neural differentiation of PC12 cells [1]. It is
absolutely fascinating to consider how a single cytokine
can exert functional pleiotropy and how the cell specificity
of cytokine action is determined.
Cytokine action can be regulated at either or both of two
major levels—outside and inside the target cells (Fig. 1).
Outside the responding cells, cytokine effects are regulated
by the duration of cytokine availability in the microenviron-
ment and by the amount of cytokine produced. The half-life
of the cytokine and the presence or absence of a matrix that
traps or concentrates the cytokine in the microenvironment
both affect the duration of a cytokine’s effect. The expres-
sion of cytokine receptors on the surface of cells determines
which cells surrounding the cytokine-producing cells can
respond to the cytokine signal, as does the expression of
other components of the receptor complex. The distance and
the strength of the cell–cell interaction between responding
cells and cytokine-producing cells also affect the duration
and intensity of the cytokine’s effects.
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Inside the cells, cytokine signals are regulated at the
plasma membrane, in the cytoplasm, and in the nucleus.
Upon the binding of a cytokine to its specific receptor, a
given set of transduction pathways is activated in a manner
dependent on the kinases or phosphatases that are constitu-
tively associated with the given receptor. The cytoplasmic
tail of each cytokine receptor has multiple structures that
determine signaling pathways by recruiting kinases, phos-
phatases, and transcription factors. Adaptor molecules play
pivotal roles in the positive or negative regulation of certain
signaling pathways and in the integration of several path-
ways. The set of genes transcribed by a specific transcrip-
tion factor helps determine the biological output. Further-
more, a given target cell simultaneously receives multiple
signals through independent receptors, and these signals
converge or engage in cross-talk inside the cells.
To explain how a cytokine receptor complex transduces
cell-specific signals, we will focus much of our discussion
here on the IL-6 receptor as a model system for cytokine
receptors (Fig. 2). The cytokine receptor complex consists
of a heterodimer. The soluble form of a cytokine receptor
can function as a competitive inhibitor by hindering the
binding of cytokine to its receptor. However, in certain
cases, the complex of a cytokine and the soluble form of its
receptor acts as a novel cytokine, as in the case of the
complex of IL-6 and the soluble form of IL-6Ra [2–4]. The
signal-transducing subunit of cytokine receptors usually
does not have enzyme activity in the cytoplasmic tail, but
has several motifs that serve as binding sites for downstream
signal-transducing molecules. Ligand binding to a cytokine
receptor induces the homo- or heterodimerization of the
receptor subunits and activates the JAK family tyrosine
kinases, which induce the tyrosine phosphorylation of the
receptor’s cytoplasmic tail [5]. Some of these phosphory-
lated tyrosines can serve as a docking site for signal trans-
ducer and activators of transcription (STATs), which bind to
the phosphotyrosine with their SH2 domain. The STAT
proteins are then tyrosine-phosphorylated, resulting in their
dimerization and acquisition of high-affinity DNA-binding
activity, which facilitates their action as nuclear transcription
factors [6,7]. In the case of receptors for IL-6 family
cytokines, the receptor subunit gp130 induces two major
signal transduction pathways, mediated by Stat3 and SHP-2/
Gab/extracellular signal-regulated kinase mitogen-activated
protein kinase (ERK MAPK), respectively [8]. In general,
signals elicited by a ligand binding to its receptor are
transduced to the nucleus by a cascade of reactions involv-
ing multiple signal transducers or adaptors. This multi-step
pathway causes diversification in the nature of the signals.
Each signal transducer or adaptor not only transfers signals
to the next molecule in the cascade, but also amplifies,
attenuates, or converts the signals, or directs them into
different branches of the pathway (Fig. 3). Furthermore,
the multi-step signal transduction provides opportunities to
Fig. 1. Factors involved in the determination of cell specificity of a cytokine and factors involved in the determination of cell specificity of a cytokine.
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feed the results of one pathway into another, leading to
plasticity in the entire signal transduction mechanism. These
multiple pathways usually include contradictory signals,
such as pro- and anti-apoptotic signals, or growth and
differentiation signals.
2. Cell specificity at the level of the cytokine receptor
The IL-6 receptor complex consists of an IL-6-binding
molecule called IL-6Ra and gp130, a common signal trans-
ducing subunit of the receptors for IL-6 family cytokines
[2]. The cytoplasmic domain of IL-6Ra is not required for
signal transduction [9,10]. The binding of IL-6 to IL-6Ra
triggers the association of IL-6Ra with gp130 [11], leading
to the formation of a hexamer composed of two each of IL-
6, IL-6Ra, and gp130 [12,13]. Gp130 is shared by the
receptors for CNTF, LIF, OSM, IL-11, and CT-1 and is
critically involved in the signal transduction through these
receptors [2]. Among the receptors for the IL-6 family
cytokines, the IL-6 receptor complex and the IL-11 receptor
complex consist of a binding subunit and a signal-trans-
ducing subunit. On the other hand, there are receptor
complexes that consist of two subunits that can both trans-
duce signals. The oncostatin M receptor consists of a
heterodimer of the oncostatin M receptor and gp130, both
of which have long cytoplasmic tails with tyrosine residues.
The receptor complexes for LIF, CNTF, and Cardiotropin 1
are composed of the LIF receptor and gp130. Ligand bind-
ing to the IL-6 or IL-11 receptor complex results in the
homodimerization of gp130, whereas ligand binding to
OSMR or LIFR results in heterodimerization. There are
several examples indicating the induction of distinct
responses that depend on the signaling from homodimeric
or heterodimeric gp130. In hepatic cells, OSM, LIF, and IL-
6 induce the expression of similar sets of acute-phase
plasma protein genes, but stimulation of OSMR (OSMR/
gp130 heterodimer) and LIFR (LIFR/gp130 heterodimer)
induces higher STAT5b activation than does stimulation of
IL-6R (gp130homodimer) [14]. Furthermore, overexpres-
sion of the transcription factor SCL inhibits the LIF- and
OSM-, but not the IL-6-mediated induction of M1 cell
differentiation, suggesting that the LIF receptor/gp130 het-
erodimers use an SCL-inhibitable pathway while gp130
homodimers do not [15]. In embryonic stem cells, LIFRh-
gp130 heterodimerization or gp130 homodimerization can
transmit a self-renewal signal, but the LIFRh homodimeri-
zation does not [16]. These results indicate that, depending
on the expression of the partner subunits for gp130 on the
cells, ligand binding induces the homodimerization of
gp130 or heterodimerization of gp130 and another receptor,
and the cells receive common signals from gp130 and
additional signals from the partner receptors, which result
in a variety of responses in different cells.
Because the expression of gp130 is ubiquitous, the
expression of a receptor subunit unique to each cytokine is
the factor that determines which cells respond to which IL-6
Fig. 2. A schematic model for a cytokine– receptor complex. In the case of
IL-6 receptor, it consists of a IL-6 binding receptor, a chain and signal
transducer, gp130, which is shared among the IL-6 family cytokine
receptors. A signal transducing subunit of cytokine receptors usually do not
have enzyme activity in their cytoplasmic tails, but have several motifs of
the binding sites for downstream signal transducing molecules. Ligand
binding to cytokine receptor induces homo- or heterodimerization of the
receptor subunits and activates JAK family tyrosine kinases which induce
tyrosine phosphorylation of cytoplasmic tail of the receptors. By IL-6
family cytokines, gp130 generates two major signal transduction pathways:
Stat3- and SHP-2/Gab/ERK MAPK-mediated ones. In general, signals
elicited by the ligand binding to its receptors are transduced to the nucleus
by the cascade of reactions of multiple signal transducers or adaptors.
Fig. 3. Roles for signaling molecules. Relay: The cascade of mitogen-
activated protein kinase (MAPK) consists of a MAPK kinase kinase
(MAPKKK), a MAPK kinase (MAPKK), and aMAPK.MAPKKKs activate
MAPKKs by phosphorylation at two conserved serine residues and
MAPKKs activate MAPKs by phosphorylation at conserved threonine and
tyrosine residues. The cascade relays signals from the plasma membrane to
targets in the cytoplasm and nucleus simply by phosphorylation and
activation of kinases. Attenuate: Activation of InB kinase induces
phosphorylation of InB that leads to the ubiquitination and proteolytic
degradation of InB. Thus InB kinase attenuates the function of InB. Convert:
TNFR2 of naı¨ve T cells transduces anti-apoptotic signals. Once T cells are
activated, the serine/threonine kinase RIP is induced and TNFR2 is
converted to transduce signals of apoptosis. Branch: Cytokine signal
induces complex formation of Gab1/Gab2 with SHP-2 and PI3 kinase, which
generates two signaling pathways of ERK MAP kinase and PI3 kinase.
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family cytokines. While all thymocytes express gp130
throughout thymic maturation, IL-6Ra expression in the
thymus is limited to CD4 or CD8 single-positive cells [17].
Among B lymphocytes, IL-6Ra is expressed on the acti-
vated B cells or plasma cells but not on resting B cells [18].
Thus, stage-specific expression of a unique receptor subunit
has roles in regulating the stage or lineage of the responding
cells. Interestingly, a complex of IL-6 and soluble IL-6Ra
can activate cells that express only the gp130 receptor
subunit. For example, certain cells, such as endothelial cells,
express gp130 without IL-6Ra, but IL-6 can provide signals
through gp130 if the soluble form of IL-6Ra is available
(Fig. 4). This type of signal transduction is not restricted to
the IL-6 receptor system. IL-12 consists of a heterodimer of
40 kDa (p40) and 35 kDa (p35) subunits [19]. The amino
acid sequences of p35 and p40 resemble IL-6 and the soluble
form of IL-6Ra, respectively, suggesting that IL-12 activates
target cells in a manner similar to the complex of IL-6 and
soluble IL-6Ra. This interpretation is further supported by
the fact that IL-12R is the member of the cytokine receptor
superfamily that is most closely related to gp130 [20].
Another example from the IL-6 family cytokines involves
CNTFRa, a glycosyl-phosphatidyl inositol (GPI)-anchored
molecule. The complex of soluble CNTFRa and CNTF can
activate cells expressing LIFRh and gp130 [21]. Further-
more, soluble IL-11R and IL-11 can transduce signals for
differentiation into M1 cells expressing gp130 but not IL-
11R [22]. As mentioned above, the restricted expression of a
unique receptor subunit regulates which cells respond to a
cytokine, but the presence of a soluble receptor breaks the
specificity. These examples that naturally use this system
indicate that this is a novel mechanism by which the
cytokine systems generate functional diversity; thus, we
have named it the ‘‘Receptor Conversion model’’ (Fig. 4)
[2,3]; this process is also known as ‘‘Transactivation’’ [4].
According to this model, a complex consisting of a
soluble cytokine receptor and its corresponding cytokine
ligand acquires a target specificity that is different from that
of the original cytokine, leading to the expression of a
distinct function from the original cytokine [2–4,23].
Experimentally, double transgenic mice expressing human
IL-6 and soluble IL-6Ra show myocardial hypertrophy
[24], extraordinary expansion of hematopoietic progenitor
cells [25], nodular regenerative hyperplasia, and adenomas
of the liver [26], indicating that the complex of IL-6 and
soluble IL-6Ra acts on heart muscle cells and hematopoietic
stem cells, which express gp130 but not IL-6Ra and on
which IL-6 alone cannot act. Thus, by forming a complex
with the soluble receptor, IL-6 apparently acquires novel
biological activities. There are several physiological or
pathological situations where receptor conversion may hap-
pen. Soluble forms of CNTFRa are present in the cerebro-
spinal fluid and released from skeletal muscle in response to
peripheral nerve injury [27]. Soluble IL-6Ra is detected in
the sera of patients with inflammatory diseases such as
rheumatoid arthritis [28] and can stimulate endothelial cells
in the presence of IL-6. Stimulation of endothelial cells with
IL-6 and soluble IL-6 induces chemokine production, which
affects the recruitment of leukocytes [29,30]. In the case of
inflammatory bowel diseases, soluble IL-6Ra released from
monocytes may be involved in T-cell activation [29,31]. The
receptor conversion model may be applied to a wide range
of receptor systems. Furthermore, novel drugs could be
designed on the basis of this model. In an elegant experi-
ment, Fischer et al. [32] developed a bioactive designer
cytokine composed of soluble IL-6Ra and IL-6 linked to
each other by a flexible peptide chain. This designer
cytokine can effectively induce the expansion of hemato-
poietic progenitor cells.
Soluble receptors also play a role in the negative regu-
lation of cytokine signals. Soluble LIFR can bind LIF but is
unable to transduce a signal and thus behaves as a LIF
antagonist [33]. It is noteworthy that a soluble receptor can
play both agonistic and antagonistic roles depending on the
receptor components expressed on the surface, as shown in
the case of IL-11R [22]. Soluble IL-11R in the presence of
IL-11 can induce growth inhibition, as a parameter of
macrophage differentiation, of M1 cells that do not express
IL-11R. When the M1 cells expressing IL-11R (M1/IL-11R)
were used, IL-11 alone induced growth inhibition but
soluble IL-11R + IL-11 could not [22]. Specific binding of
IL-11 to M1/IL-11R was inhibited by the presence of
soluble IL-11R, probably because the binding affinity for
membrane IL-11R and gp130 is higher than that for soluble
IL-11R and gp130, and free gp130 is not available on the
surface of M1/IL-11R. Several members of the TNF/TNFR
superfamily have decoy receptors that lack a functional
cytoplasmic domain. They are membrane-anchored or solu-
ble forms. Soluble Fas is an alternatively spliced form,
Fig. 4. Receptor conversion model. (Left) A cytokine acts on the cells that
express a specific receptor. (Right) With certain cytokines, a complex
composed of the cytokine and a soluble form of its receptor subunit can act
on the cells that only express another receptor subunit and do not respond to
the cytokine alone. By this way, the complex acts on a novel target cell on
which original cytokine cannot act, and exerts completely different
biological activities.
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whereas soluble TNFR1 is a cleaved form. Due to the much
lower activity than the membrane-bound forms, soluble Fas
can have the opposite function of the membrane-bound
receptors and protect cells from apoptotic signals. The
production of soluble FasL by tumors may help tumors
escape from immune surveillance. It is known that in spite
of the expression of death receptors and their ligands,
lymphocytes in the early phase of activation are resistant
to death induced by the ligation of the death receptor. The
expression of TNFR molecules lacking a functional cyto-
plasmic domain may contribute to this resistance. Further-
more, several viruses that produce the soluble form of
cytokine receptors also escape from immune defense mech-
anisms [34].
In addition to soluble receptors, a cytokine-like molecule
that binds to the receptor but cannot elicit signals, i.e., a
receptor antagonist, also plays negative regulatory roles.
The IL-1 receptor antagonist (IL-1Ra) is a member of the
IL-1 family that binds to IL-1 receptors but does not induce
an intracellular response [35]. Hepatic cells produce soluble
IL-1Ra in acute-phase responses. A protective role of IL-
1Ra in septic shock has been suggested by the results of
injecting lipopolysaccharide (LPS) into IL-1Ra knockout
mice, which exhibited increased lethality. Recently, it has
been reported that IL-1Ra knockout mice of the Balb/c
background develop spontaneous arthritis that resembles
human rheumatoid arthritis [36], suggesting a protective
role for IL-1Ra against chronic inflammatory diseases.
3. Cell specificity inside cells
For the cytokine receptor systems described above, there
are three models for the generation of cell-type-specific
downstream signals that are currently under consideration
(Fig. 5). The first is that the specificity is determined by the
set of downstream molecules expressed in each cell. The
second is that a balance of contradictory signals determines
the final output of the signal. The third model is that in spite
of the same sets of initial pathways being utilized immedi-
ately after receptor activation, modification of selective
downstream pathways results in signals of different nature.
These three models are not mutually exclusive.
3.1. A set of signaling molecules expressed by the cells
determines the specificity
The first model relies on different cell types expressing
different sets of signaling molecules. For example, the
cytokine receptor on cell type A might use multiple signal-
ing molecules 1, 2, and 3; the same cytokine receptor on cell
type B could use a distinct set of signaling molecules, 4, 5,
and 6, that are expressed by that cell type. As a result, cells
A and B receive distinct signals from the same cytokine
receptor. Because the recruitment of signaling molecules to
the cytokine receptor is restricted by the specific motifs
found on the receptor cytoplasmic tail, lineage-specific
isoforms of signal transducers could play alternate roles in
different cells. In this case, due to the conservation of
critical domains in the family members, usage of another
family member is not likely to result in much difference in
the nature of the signals as a whole. Adaptor molecules that
are expressed in a lineage- or stage-specific manner may
play more critical roles in this model. For example, the
adaptor Gab1 is expressed in murine marginal zone B cells
but not in follicular B cells [37], and Gab2 but not Gab1 is
expressed in murine bone marrow-derived mast cells [38].
Other factors that are involved in this specificity include the
Fig. 5. Models for the generation of cell-type specific downstream signals. Model 1: a distinct set of downstream signal-transducing molecules. Model 2:
balance of contradictory signals. Model 3: modification of selective downstream pathways. Variable combination of these three mechanisms determines the
final outcome of signaling.
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lineage- or stage-specific expression of transcription factors
and repressors, and the accessibility of particular genes to
transcription.
3.2. Balance of contradictory signals determines the cell
specificity of the signal
The second model is based on the fact that the simulta-
neous activation of multiple pathways that produce contra-
dictory signals is common in the signal transduction of
cytokine receptors, which are typically represented by
gp130 and the TNF receptor (TNFR) superfamily. IL-6
can simultaneously induce growth-suppressing and
growth-enhancing signals in murine leukemic M1 cells.
When STAT3 activation is suppressed, gp130 stimulation
induces growth-promoting rather than growth-suppressing
signals in a manner that is dependent on a tyrosine residue
that is essential for MAPK activation. CNTF promotes the
differentiation of cortical precursor cells into astrocytes
through STAT3 activation, while MAPK activation through
gp130 is suppressive for astrocyte development. On the
other hand, gp130-induced neurite growth in PC12 cells
depends on gp130-mediated MAPK activation, while
STAT3 activation is inhibitory [39]. Similarly, gp130 can
activate the signals for the cell-cycle transition from G1 to S
phase in a STAT3-dependent manner, and at the same time,
can induce a p21 cyclin-dependent kinase inhibitor that
opposes these STAT3-dependent signals [40]. These contra-
dictory signals originate at distinct cytoplasmic regions of
gp130. As a final example, activation of TNFR1 results in
the stimulation of the cell death pathway or induction of a
protective pathway mediated by the activation of the nuclear
transcription factor nB (NF-nB), or both.
These findings, showing that cytokine receptors can send
simultaneous contradictory signals, seem surprising,
because one might expect that a cytokine would induce
only well-coordinated signals, and not contradictory, chaotic
signals, to express a unified biological activity in a given
target cell. Nevertheless, cytokines and growth factors
generally seem to have the potential to simultaneously
induce contradictory intracellular signaling pathways. In
such a system, it is reasonable to hypothesize that a ‘‘con-
ductor’’ exists that can orchestrate or regulate the balance of
the conflicting signals to elicit a unified output. We have
called this model the ‘‘orchestrating model’’ (Fig. 6)
[2,3,40]. Such a conductor could be a transcription factor,
protein kinase, phosphatase, or scaffolding/docking mole-
cule. This regulation may not be apparent, but can be
recognized when a conversion of the final output is
observed upon modulation of the putative conductor. In
the case of gp130, the suppression of STAT3 activation can
change the biological activity of IL-6 on M1 cells from
growth suppression to enhancement [41]. Among the TNF/
TNFR superfamily members, there exists a subset of recep-
tors that have a death domain (DD) and are often called
death receptors. Ligand engagement causes the association
of adaptors such as the Fas-associated DD protein (FADD)
and the TNFR-associated DD protein (TRADD) that ulti-
mately cause caspase activation and cell death [42]. These
adaptors transduce contradictory anti-apoptotic and pro-
apoptotic signals [43]. Two principal classes of cytoplasmic
adaptor proteins, TRAFs (TNFR associated factors) and
DD molecules, link ligand binding with a survival signal
(NF-kB activation) and a death signal (caspase-8/FLICE
activation), respectively. The balance of the pro- and anti-
apoptotic signals, however, is carefully regulated by con-
ductor-like molecules, FLIP (FLICE-like inhibitory protein)
and RIP, a serine/threonine kinase (Fig. 7).
Death signals from Fas are negatively regulated by FLIP,
a cytosolic molecule (Fig. 7A). The resistance of naı¨ve T
cells to activation-induced cell death has been partly attrib-
uted to high levels of intracellular FLIP, which competi-
tively inhibits the binding of caspase-8/FLICE to FADD and
shuts off Fas signaling [44]. FLIP homologs were identified
in virus (vFLIP) and mammalian cells (cFLIP) by searching
a database with the sequence of the death effector domain
Fig. 6. An orchestrating model for the contradictory signals elicited by
cytokines. Although distinct cytoplasmic regions of a cytokine receptor
simultaneously generates contradictory signals, the resulting chaotic
situation could be orchestrated by a conductor, for example STAT3, to
effect a directed biological action, thus bringing order from chaos.
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(DED) on caspase-8 [45], which is required for its inter-
action with FADD. Because cFLIP has a DED but does not
have caspase-8 activity, the presence of FLIP interferes with
the activation of caspase-8 at the level of the death-inducing
signaling complex (DISC). Thus, FLIP could be a conductor
that attenuates death signals from Fas. cFLIP expression is
down-regulated in activated T cells, B cells, and macro-
phages, and its downregulation corresponds to an increase
in the sensitivity of these cell types to death signals.
In the case of TNFR1, the serine/threonine kinase RIP
could be a conductor (Fig. 7B) [46]. RIP has a DD, interacts
weakly with the death receptor TNFR1, and is essential for
NF-nB activation but not for apoptosis induced by TNFa.
Mouse fibroblasts are normally resistant to TNFR1-induced
apoptosis due to the strong anti-apoptotic effects of acti-
vated NF-nB, but become sensitive in the absence of RIP
[47]. On the other hand, in human T cells, RIP is needed for
the TNFR1-mediated induction of both death and NF-kB
activation [48], indicating that the action of RIP downstream
of TNFR1 depends on the cell type.
The nature of the unified signal from TNFR2 depends on
the level of RIP expression in T cells (Fig. 7C). In resting or
activated T cells that have not been exposed to IL2 and do
not express RIP, TNF activates NF-kB through TNFR2 and
a TRAF2-dependent pathway [49]. Thus, TNFR2 induces
anti-apoptotic signals. However, in activated T cells that
have been exposed to IL2, RIP is induced and is proposed to
act as a bridge between the TNFR2-TRAF2 complex and
FADD/MOLT1 and the apoptosis machinery. Thus, the
activation-induced expression of RIP determines the direc-
tion of TNFR2 signals containing contradictory signals,
indicating that RIP plays a role as a conductor. These
orchestrating mechanisms may, at least in part, underlie
the functional pleiotropy that is a characteristic feature of
cytokine action.
3.3. Modulation by feedback or cross-talk determines the
cell specificity of the signals
In the third model, a signaling pathway can be modulated
in two ways. One is by positive or negative feedback and
the other is by cross-talk (Figs. 8 and 9). To this end, it is
important how the termination of cytokine signaling is
controlled. For example, the activated states of gp130,
JAK, and STAT3, which are initiated by tyrosine phosphor-
ylation, are quickly shut down by dephosphorylation. The
negative-feedback circuit independent of de novo protein
synthesis is through the SH2-containing phosphatase, SHP-
2, which is recruited to tyrosine 759 of gp130 and activated
by the stimulation of gp130 (Fig. 8A). In embryonic
fibroblasts expressing gp130 with a point mutation that
changes tyrosine 759 to phenylalanine, the tyrosine phos-
Fig. 7. Signaling of TNF/TNFR superfamily and conductor-like molecules, FLIP and RIP. Receptor cascades utilized in distinct T-cell activation states are
shown.
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phorylation of gp130, JAK, and STAT3 is prolonged,
indicating the presence of negative regulatory signals that
begin simultaneously with the activation.
3.3.1. Feedback
Two families of proteins, the SOCS and PIAS families,
are involved in less direct feedback mechanisms that down-
Fig. 9. Various modes of cross-talk operate at multiple points of signal transduction pathway.
Fig. 8. Modes of negative and positive feedback. Modes of negative feedback by phosphatase (A), SOCS1 (B), SOCS3 (C), PIAS (D) and positive feedback by
SBE (E) are illustrated.
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regulate cytokine signals. The SOCS family is comprised of
eight members, SOCS-1 through SOCS-7 and cytokine
inducible SH2-containing protein (CIS). The genes for
several of these members were identified as immediate-early
genes induced in response to several cytokines [50]. Each of
these proteins contains two regions of homology, a central
SH2 domain and SOCS box and a C-terminal 40-aa motif.
CIS is a negative regulator of STAT5 activation in response
to several cytokines, including EPO, IL-2, and IL-3. SOCS-
1 was identified as an inhibitor of the IL-6-induced differ-
entiation of murine monocytic leukemic M1 cells, as a JAK-
binding protein, and as a protein with an SH2 domain
similar to that of the STAT proteins [51–53]. SOCS-1 binds
to all four JAK kinases through its central SH2 domain and
inhibits their kinase activity (Fig. 8B). In vitro study has
revealed that SOCS-1 inhibits the STAT activation induced
by interferon, IL-6, IL-4, and LIF. In addition to the
inhibition of the JAK kinases, SOCS-1 also inhibits Tec
kinase, Vav function, and c-kit-mediated proliferation in
vitro.
The expression of socs-3 mRNA is induced by CNTF
[54], LIF [55], IL-2 [56], IL-6 [53], IL-11 [57], leptin [58],
prolactin [59], and growth hormone [60]. Overexpression of
SOCS-3 results in the inhibition of signaling by each of
these cytokines and the association of SOCS-3 with JAK,
growth hormone receptor, IL-2Rh, and gp130. Unlike
SOCS-1, SOCS-3 does not inhibit the kinase activity of
JAK1 or JAK2. Recently, it was reported that Tyr-759 of
gp130 also acts as a docking site for SOCS3 (Fig. 8C)
[61,62]. SOCS-1-deficient mice die perinatally because of
excessive IFN-g responses [63,64]. SOCS-3 deficient mice
die embryonically, probably because of excessive fetal
erythropoiesis [65]. Besides cytokines, CIS is also induced
in T cells by T-cell receptor (TCR) stimulation [66], sug-
gesting that the TCR signal can negatively regulate cytokine
signals. Similarly, the IL-6 signal is negatively regulated by
stimulation with basic fibroblast growth factor (bFGF),
which activates MAP kinase and rapidly induces SOCS3
expression [67].
Cytokine signals are also negatively regulated by the
binding of STAT to DNA. PIAS3 (protein inhibitor of
activated STAT) binds to STAT3, but not STAT1, blocking
the DNA-binding activity of STAT3 and inhibiting STAT3-
mediated gene activation (Fig. 8D) [68]. Similarly, PIAS1
blocks the DNA-binding activity of STAT1 and inhibits
STAT1-mediated gene activation in response to interferon
[69].
Cytokines regulate acute-phase responses and immune
responses against invading microorganisms, and the rapid
induction of these biological responses is critically impor-
tant. A positive regulatory mechanism has been reported at
the level of stat3 gene expression in the IL-6 response.
Treating mice with IL-6 increases the levels of stat3 mRNA
in the liver [70]. IL-6 induces stat3 mRNA in cell lines
through an IL-6 response element in the promoter contain-
ing both a low-affinity STAT3-binding element (SBE) and a
cyclic AMP-responsive element (CRE), indicating that the
stat3 gene is upregulated by STAT3 itself in M1 cells (Fig.
8E) [71]. The analysis of knockin mice with a mutation in
the SBE revealed that this element is used in the spleen and
kidney, but not in the liver after IL-6 injection, indicating
that autoregulation of the stat3 gene operates in vivo in a
tissue-specific manner [72]. Furthermore, thymocytes from
mutant SBE mice showed an impairment of the IL-6-
induced stat3 transcription and reduced growth by stimula-
tion with anti-CD3 + IL-6, suggesting this autoregulation
may be important in the initiation of immune responses.
3.3.2. Cross-talks at receptor levels
As evidence of cross-talk at the receptor level (Fig. 9A),
an interaction between IL-6R and the growth factor recep-
tors Erb2 and Erb3 was reported in prostate carcinoma cells,
but was not observed in hematopoietic cells. IL-6 induces
the formation of a complex between gp130 and ErbB2, the
activation of ErbB2 and MAP kinase, and the growth of
prostate carcinoma cells, indicating that the IL-6 receptor
can recruit different signal transducers in different cells to
generate varied responses [73]. Cross-talk at the receptor
level has also been shown in the case of a breast carcinoma
cell line [74]. In these cells, IL-6 and oncostatin M simulta-
neously inhibit cell proliferation and increase cell migration.
The inhibition of growth is mediated by STAT3, whereas
migration is mediated by a MAP kinase and phosphatidy-
linositol 3 kinase (PI3K). In this carcinoma, SHP2 and Gab1
are constitutively associated with the active EGF receptor,
and IL-6-induced activation of MAPK is largely dependent
on EGFR activity, indicating that IL-6 acts in synergy with
EGF autocrine activity to signal through the MAPK/PI3K
pathways.
Cross-talk between the IFN-g receptor (IFNGR1) and the
IFNa/h receptor (IFNAR1), which are localized to the
caveolar membrane domain, is important for the maximal
antiviral responses by IFN-g [75]. In mouse embryonic
fibroblasts (MEF) lacking IFNAR1, the IFN-g-induced
antiviral response is impaired. The IFN-g-induced DNA-
binding activity of STAT1 is lower and the formation of the
ISGF3 (IFN-stimulated gene factor 3) complex is not
detectable. IFN-h-null MEF also showed a deficiency in
the IFN-g-induced STAT1 activation and antiviral response
[75]. This deficiency was rescued by IFN-h added exoge-
nously at a low concentration, which by itself did not
activate STAT1, indicating the importance of a constitutive
subthreshold level of IFN-a/h signaling in the absence of
virus infection, for a full IFN-g response. Through the
constitutive subthreshold IFN-a/h signaling, IFNAR1 is
tyrosine-phosphorylated and associates weakly with
IFNGR2 (the nonligand-binding component of the IFNGR
complex), and STAT1 associates with IFNAR1.
3.3.3. Cross-talks at cytosolic transcription factors
Beyond the level of the receptors, many signaling mol-
ecules, such as kinases, phosphatases, adaptor molecules,
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and transcription factors are commonly used in the signaling
pathways of distinct cytokines. Thus, these signaling mol-
ecules could also be points of cross-talk (Fig. 9B,C). In the
following paragraphs, we provide several examples of such
signaling pathways.
IL-11 is an anti-inflammatory cytokine that can reduce
the production of inflammatory mediators such as TNF-a,
IL-1h, IL-12, IL-6, and nitric oxide. IL-11 reduces the levels
of LPS-induced TNF-a, IL-1h, IL-6, and IL-12p40 mRNA
in activated macrophages. IL-11 treatment reduces the levels
of NF-nB binding activity by maintaining the levels of
inhibitors of NF-nB, InB-a, and InB-h, suggesting that
the anti-inflammatory effects of IL-11 are mediated by the
inhibition of NF-kB-dependent transcriptional activation
[76].
TGF-h and IFN-g have opposite effects on diverse
cellular functions. TGF-h signals through a receptor serine
kinase that phosphorylates and activates the transcription
factors Smad 2 and 3, whereas the IFN-g receptor and its
associated protein tyrosine kinase Jak1 mediate the phos-
phorylation and activation of the transcription factor STAT1.
IFN-g inhibits the TGF-h-induced phosphorylation of
Smad3, the association of Smad3 with Smad4, the accumu-
lation of Smad3 in the nucleus, and the activation of TGF-h-
responsive genes. Acting through Jak1 and STAT1, IFN-g
induces the expression of Smad7, an antagonistic SMAD,
and Smad7 prevents the interaction of Smad3 with the TGF-
h receptor. In this way, the cross-talk between the TGF-h
and IFN-g signals leads to their integration [77].
Pathogenic and proinflammatory stimuli and TGF-h
exert opposing activities in cellular and immune responses.
In response to TNF-a stimulation, the RelA subunit of NF-
nB (NF-nB/RelA) induces the phosphorylation, nuclear
translocation, and DNA binding of the SMAD signaling
complexes [78]. The antagonism is mediated through the
up-regulation of Smad7 synthesis and the induction of stable
associations between ligand-activated TGF-h receptors and
inhibitory Smad7. Following stimulation with bacterial LPS
or the proinflammatory cytokines TNF-a and IL-1h, NF-
nB/RelA induces Smad7 synthesis through the activation of
Smad7 gene transcription [78].
After cells are stimulated with growth factors or cyto-
kines, the STAT transcription factors are phosphorylated on
tyrosine and translocate into the nucleus. Upon stimulation,
STAT3 is phosphorylated on Ser-727 and Tyr-705. IL-6-
induced STAT3 transactivation and Ser-727 phosphorylation
is independent of ERK-1 or JNK-1 activity, but involves a
gp130 receptor-signaling cascade that includes Vav, Rac-1,
MEKK, and SEK-1/MKK-4 as signal transduction compo-
nents [79]. IL-6 activates Rac-1 and SEK-1/MKK-4 of the
stress-activated protein kinase pathway, as well as protein
kinase Cy (PKCy), as indicated by PKCy Thr-505 phos-
phorylation. However, JNK-1, the end-point kinase of this
stress-activated signal transduction cascade, is not activated
by IL-6 [80]. Dominant-negative Rac1 guanosine triphos-
phatase inhibits STAT3 activation by growth factors,
whereas activated Rac1 stimulates STAT3 phosphorylation
on both tyrosine and serine residues. Moreover, activated
Rac1 forms a complex with STAT3. Yeast two-hybrid
analysis indicates that STAT3 binds directly to active but
not inactive Rac1 and that the interaction occurs via the
effector domain. Thus, Rac1 may serve as an alternate
mechanism for targeting STAT3 to tyrosine kinase signaling
complexes [81].
When a low concentration of IL-6 is used, the regulation
of STAT3 phosphorylation is different. Ser-727 is required
for the full transcriptional activity of STAT3. IL-6 activates
at least two distinct STAT3 serine kinase pathways and an
H7-sensitive pathway is dominant over a PD98059-sensitive
one. The YXXQ motif of gp130 is sufficient for the H7-
sensitive STAT3 Ser-727 phosphorylation. This YXXQ-
mediated pathway does not involve ERK, p38, JNK, or
PKCy, and requires a site in the region from 533 to 711 of
STAT3 for phosphorylation in vivo [82]. These studies
indicate that serine- and tyrosine-phosphorylation of the
STATs are regulated by multiple systems and can provide
points for cross-talk (Fig. 9C).
Several cytokines have been shown to act synergistically
with various hematopoietic growth factors that use the Jak–
STAT pathways, in vivo and in vitro. The phosphorylation
states of STAT can be a point of cross-talk regulated by
other signaling pathways. Stem cell factor (SCF) induces the
serine but not tyrosine phosphorylation of STAT3 in the
human growth factor-dependent cell lines MO7e and TF-1.
The selective serine phosphorylation of STAT3 also occurs
in response to the stimulation of cells with granulocyte-
macrophage colony-stimulating factor and IL-3. Simultane-
ous stimulation with SCF plus other cytokines that induce
the tyrosine phosphorylation of STAT3, such as IL-9 in
MO7e cells or IL-6 in TF-1 cells, results in the tyrosine
phosphorylation and enhanced serine phosphorylation of
STAT3. Although serine phosphorylation alone does not
promote the nuclear translocation of STAT3 or the DNA-
binding activity of its cis-inducible element, costimulation
with SCF plus IL-9 in MO7e cells results in the nuclear
translocation of serine-hyperphosphorylated STAT3. These
results suggest that SCF or other cytokines might modulate
the signals of the Jak-STAT pathway through the serine
phosphorylation of STAT3 [83]. In another example, anti-
inflammatory cytokine IL-10 directly inhibits the STAT-
dependent early response gene expression induced by both
IFNa and IFNg in monocytes by suppressing the tyrosine
phosphorylation of STAT1 [84].
3.3.4. Cross-talks in the nucleus
After transcription factors enter the nucleus for DNA
binding or transcription, they compete for binding sites or
interact with each other to transcribe particular sets of genes.
At this point, the interaction or cross-talk between tran-
scription factors results in the synergism, repression, or
integration of the transcription of certain genes (Fig. 9D–
G). Independent but closely spaced DNA-binding sites for
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STAT3 and c-Jun are required for maximal enhancer func-
tion in a number of genes, including the gene encoding the
IL-6-induced acute-phase response protein a2-macroglobu-
lin. Using fragments of STAT3 and c-Jun proteins, the
interactive sites were mapped to the C-terminal region of
c-Jun and to two regions in STAT3, within the coiled-coil
domain and in a portion of the DNA-binding domain distant
from the DNA contact sites. In transient-transfection experi-
ments with the a2-macroglobulin enhancer, STAT3 and c-
Jun cooperated to yield maximal enhancer function (Fig. 9F)
[85,86].
Cooperation between STAT3 and c-Jun results in the
suppression of Fas transcription; this suppression is often
seen in advanced human tumors. The PI3K-AKT signaling
pathway is capable of down-regulating both STAT3 and c
Jun-dependent transcription, resulting in the derepression of
Fas transcription. PI3K-AKT’s ability to affect Fas tran-
scription was not observed in c-Jun null fibroblasts, sug-
gesting that c-Jun is required for the PI3K/AKT-mediated
regulation of Fas transcription. Because the dominant-neg-
ative form of Rac1 (RacN17) is efficient in relieving Fas
expression, the increase in Fas expression following stimuli
that activate AKT could be mediated via AKT’s ability to
elicit the suppression of Rac1, which in turn decreases JNK
activities and c-Jun phosphorylation [87].
Glucocorticoids exert a synergistic effect on the IL-6-
mediated inflammatory response through a direct interaction
between IL-6-activated STAT3 and ligand-bound glucocor-
ticoid receptors (GRs). This synergism is observed even
when an MMTV-Luciferase construct that has four gluco-
corticoid responsive elements (GRE) but no IL-6 responsive
elements (IL-6RE) is used, suggesting that STAT3 can
modulate GR signaling independent of IL-6RE binding. In
this case, STAT3 is a potent co-activator of GRE-mediated
transcription. The interaction between GR and STAT3 is
different from that between GR and STAT5, by which
STAT5-mediated transactivation is enhanced but GR func-
tion at the GRE site is diminished [88,89].
There are several examples of STAT proteins competing
with other transcription factors for overlapping DNA-bind-
ing sites (Fig. 9D). The Ets family protein Elf-1 represses
IL-2Ra gene transcription by binding to an Ets-binding site
that overlaps with a STAT5-binding site [90]. IL-4 secreted
from activated Th2 cells, eosinophils, and mast cells stim-
ulates the expression of immune system genes via activation
of the transcription factor STAT6. IL-4 can suppress the
expression of the other immune-related gene products,
kappa light chain, FcgR1, IL-8, and E-selectin. IL-4 acti-
vates STAT6 in human vascular endothelial cells, and two
STAT6-binding sites are present in the promoter of the E-
selectin gene. IL-4-induced STAT6 binding does not acti-
vate E-selectin transcription but suppresses the TNFa-
induced expression of the E-selectin gene. STAT6 binds to
a region in the E-selectin gene promoter containing over-
lapping STAT6 and NF-kB binding and transcriptional
activation. This case provides an example of a STAT factor
acting as a transcriptional repressor rather than as an
activator (Fig. 9E) [91]. The gene encoding the BCL-6
transcriptional repressor is frequently translocated and
mutated in diffuse large cell lymphoma. The BCL-6 DNA
recognition motif resembles sites bound by the STATs.
BCL-6 can repress IL-4-induced transcription when bound
to a site recognized by the IL-4-responsive transcription
factor STAT6 [92].
The homologous transcriptional coactivator molecules,
p300 and CREB-binding protein (CBP), are huge nuclear
proteins that interact with numerous transcription factors
through distinct domains. They are thought to help to
activate transcription by acting as a bridge between indi-
vidual transcription factors and the basal transcriptional
machinery. STAT2 and p300/CBP are known to cooperate
in signaling induced by IFN-a. The transcription factor,
IFN-stimulated gene factor 3(ISGF3) transduces IFN-a
signals and activates the transcription of cellular antiviral
defense genes. ISGF3 consists of STAT1, STAT2, and p48.
Nuclear phosphoprotein p300 and/or CBP interacts specif-
ically with STAT2. The binding domain of STAT2, a domain
essential for ISGF3 function, is in the carboxy-terminal
segment and has transactivation potential. Adenovirus
E1A blocks the IFN-a responses, allowing viral replication.
E1A represses STAT2 transactivation and IFN-a-activated
transcription by inhibiting p300/CBP function [93]. Cross-
talk between LIF and BMP2 (bone morphogenetic protein-
2) at the transcriptional level in the nucleus has also been
reported (Fig. 9G). LIF and BMP2 signal through different
receptors and transcription factors, the STATs and Smads,
respectively. LIF and BMP2 act in synergy on primary fetal
neural progenitor cells to induce astrocytes. The transcrip-
tional coactivator p300 interacts physically with STAT3 at
its amino terminus in a cytokine stimulation-independent
manner, and with Smad1 at its carboxyl terminus in a
cytokine stimulation-dependent manner. The formation of
a complex between STAT3 and Smad1, bridged by p300, is
involved in the cooperative signaling of LIF and BMP2 and
the subsequent induction of astrocytes from neural progen-
itors. Thus, p300 is thought of as a synergistic integrator of
different signal transduction pathways [94].
3.3.5. Cross-talks at adaptor molecules
Adaptor molecules could provide a point for cross-talk
(Fig. 9B). For example, in apoptosis, activated caspase
cleaves an adaptor molecule, which inhibits TCR signals.
Gads is a hematopoietic-specific adaptor protein containing
SH2 and SH3 domains that functions in TCR signals. Gads
acts by linking SLP-76, bound by the carboxy-terminal
Gads SH3 domain, to tyrosine-phosphorylated LAT, which
contains binding sites for the Gads SH2 domain. Gads is
distinguished from the Grb2 and Grap proteins by the
presence of a 120-amino acid unique region between the
SH2 domain and the carboxy terminal SH3 domain. This
region contains a caspase cleavage site. Induction of
apoptosis in lymphocytes results in the cleavage of Gads,
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which is blocked by treatment with a caspase 3 inhibitor.
The cleavage products of Gads retain the predicted binding
specificity for SLP-76 and LAT. Expression of the Gads
cleavage products in Jurkat T cells inhibits the activation of
nuclear factor in activated T cell (NFAT) following TCR
cross linking, indicating that cleavage of Gads could
function to alter signaling downstream of the T-cell receptor
by disrupting cross talk between SLP-76 and LAT [95].
Another example is an adaptor molecule that is induced
by a cytokine signal and modifies TCR signals. Clnk (for
cytokine-dependent hemopoietic cell linker) is related to
SLP-76. Unlike SLP-76 and Blnk (B cell linker protein),
Clnk is not expressed within hemopoietic cell lineages, but
its expression in T cells, natural killer cells, and mast cells,
is strictly dependent on sustained exposure to cytokines
such as IL-2 and IL-3. CD3 stimulation induces the tyro-
sine-phosphorylation of Clnk and its association with tyro-
sine-phosphorylated polypeptide (p92). Moreover, transient
expression of Clnk enhances the TCR-induced activation of
NFAT, AP-1, and the IL-2 promoter in T cells. These results
indicate that Clnk is a cytokine-induced adaptor molecule
that augments TCR signals [96].
4. Dissecting signal transduction in vivo
As we have described above, a single cytokine uses
multiple signaling pathways, which consist of several deci-
sion points providing a variety of alternative outcomes.
Although this complexity has been elucidated by investiga-
tions using cell lines, we are eager to know how, when, and in
which cells the signaling events of a particular pathway plays
a critical role in the whole body. Transgenic and knockout
mouse technologies are powerful tools that are being used for
this purpose. Many genetically engineered mice have been
reported. Here we describe results from just two of these
genetically engineered mouse lines to demonstrate the com-
plexity of in vivo signal transduction pathways.
Gab1 and Gab2 are members of the Gab/DOS (Daughter
of Sevenless) family of adaptor molecules, which contain a
pleckstrin homology (PH) domain and potential binding
sites for SH2 and SH3 domains. Gab1 and Gab2 are tyrosine
phosphorylated in cell lines upon stimulation with various
cytokines, growth factors, and antigen receptors and interact
with signaling molecules, such as SHP-2 and PI3K. Gab1-
deficient mice die as embryos and display developmental
defects in the heart, placenta, and skin, which are similar to
phenotypes observed in mice lacking signals of the hepato-
cyte growth factor/scatter factor, platelet-derived growth
factor, and epidermal growth factor pathways [97]. Consis-
tent with these observations, ERK MAP kinases are acti-
vated at much lower levels in cells from Gab1-deficient
embryos in response to these growth factors or to stimula-
tion of the cytokine receptor gp130. Roles for Gab1 in
hematopoiesis and immune responses were examined using
the lethally irradiated mice reconstituted with Gab1-defi-
cient fetal liver cells. Gab1 is not essential for hematopoi-
esis, but an observed reduction in pre-B cells, increase in
myeloid and erythroid cells in the bone marrow, and
increase in mature macrophages in the peritoneum of these
mice suggest Gab1 is involved in the regulation of B
lymphocyte and myeloid cell development [37]. Among
humoral immune responses, type2 thymus independent (TI-
2) antigen responses of the IgM and IgG1 classes are
augmented in these mice. In vitro antibody production of
Gab1-null splenic B cells, induced by anti-y-Dextran + IL-
4 + IL-5, increases in these mice, and this increase is
corrected by the retrovirus-mediated transfer of the wild-
type Gab1 gene, indicating that Gab1 has a negative
regulatory role in B-cell differentiation. Abnormal responses
selective for TI-2 antigen are ascribed to the restricted
expression of the Gab1 gene in the marginal zone B cells
but not in follicular B cells [37].
In contrast to the Gab1-null mice, Gab2-null mice are
born healthy and develop normally. In Gab2-null mice, the
numbers of mast cells are reduced markedly in the stomach
and less severely in the skin. Bone marrow-derived mast
cells (BMMCs) express the Gab2 but not the Gab1 gene.
BMMCs from the Gab2-null mice grow poorly in response
to SCF. SCF-induced activation of ERK MAP and Akt
kinases is impaired in Gab2-deficient BMMCs. These data
indicate that Gab2 is required for mast cell development and
SCF/c-Kit signaling [38]. These results indicate that both
Gab1 and Gab2 play pivotal roles in cytokine/growth factor-
mediated MAPK activation and are positively involved in
cytokine/growth factor-mediated responses. On the other
hand, the same molecule can be negatively involved in
different cells or tissues. These are typical examples show-
ing that the expression patterns of adaptor molecules can
determine the biological function of a given signaling
molecule.
We have published reports on a series of knockin mouse
lines that we generated, in which the cytokine receptor
gp130-dependent STAT3 and/or SHP2 signals were disrup-
ted by replacing the mouse gp130 gene with human gp130
mutant cDNAs [98]. These STAT3 signal-deficient mice
(gp130FXXQ/FXXQ) died perinatally, like the gp130-deficient
mice (gp130D/D), but the SHP2 signal-deficient mice
(gp130F759/F759) were born and developed normally, indi-
cating that STAT3-mediated signals are essential for the
survival of neonatal mice. To test whether gp130 signals
were needed for the formation of neural precursor cells, we
used the neurosphere-formation assay. We found that the
striatal tissue and cerebral cortex of E14.5 mice formed
neurospheres normally in response to EGF for the
gp130F759/F759, gp130FXXQ/FXXQ, and gp130D/D mice, sug-
gesting that gp130 is dispensable for the formation of neural
stem cells in vivo. To test the ability of tissues with an
altered gp130 signal to respond to cytokines, we cultured
neural explants in the presence of IL-6 family cytokines and
looked for the presence of glial fibrillary acidic protein-
positive (GFAP+) astrocytes, whose production is stimulated
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by these cytokines. We found that the explants from the
gp130D/D mice did not respond to IL-6, CNTF, or OSM
to generate GFAP+ cells. When explants from the
gp130FXXQ/FXXQ mice were cultured with IL-6 and sIL-
6R, GFAP+ astrocytes were not generated. However,
when they were cultured with CNTF or OSM, the
generation of GFAP+ astrocytes was delayed, but GFAP+
cells could be found 7 days later. These results suggest
that gp130-mediated STAT3 signaling is required for the IL-
6-induced formation of GFAP+ astrocytes, but CNTF and
OSM, which activate STAT3 through the LIF receptor h, can
compensate for the lack of gp130-mediated STAT3 signals.
At E18.5, a normal number of GFAP+ astrocytes were
detected in the marginal zone of the cervical spinal chord of
wild-type as well as gp130FXXQ/FXXQ fetuses, but not in
gp130D/D fetuses, suggesting that IL-6 family cytokines such
as CNTF and LIF are involved in the generation of astrocytes.
gp130F759/F759 mice displayed splenomegaly and lympha-
denopathy and an enhanced acute-phase reaction. MEF from
the gp130F759/F759 mice showed a prolonged gp130-induced
STAT3 activation, indicating that SHP2 or Y759-SHP-2
binding sites play a negative regulatory role in gp130 signal-
ing. Th1-type cytokine production and IgG2a and IgG2b
production increased in the gp130F759/F759 mice, while they
decreased in using the lethally irradiated mice reconstituted
with fetal liver cells from gp130FXXQ/FXXQ mice. Further-
more, gp130F759/F759 showed increased susceptibility to
Listeria infection due to the insufficient production IFNg in
the innate immune phase [99]. These results indicate that the
balance of positive and negative signals generated through
gp130 regulates immune responses.
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